Eli Lilly backs AI drug startup Absci with $40M bet on injectable antibodies

Key takeaway

• Eli Lilly invested $40 million（約64億円） in Absci, an AI drug discovery startup, as part of a $100 million（約160億円） funding round that closed after positive Phase 1 safety data on ABS-201, an AI-designed injectable antibody for hair loss and endometriosis.

• The deal reflects a shift in pharma's approach to drug development: AI tools are becoming cheaper and more widely available, so the real leverage for companies like Absci lies in owning the drug itself rather than licensing the AI technology, combined with lower-cost clinical trials in China.

3 Key Points

FAQ

What drug did Absci design with AI, and what does it treat?

Absci designed ABS-201, an injectable antibody targeting the prolactin receptor. It is meant to treat both androgenetic alopecia (male or female pattern baldness) and endometriosis, and no approved existing injectable antibody currently treats either condition.

Why does Lilly think combining ABS-201 with a GLP-1 drug matters?

Lilly CEO Sean McClain suggested the idea of eventually fusing ABS-201 with a GLP-1 compound to create one shot for both hair regrowth and weight loss—what he called 'total vitality at an affordable price.' The strategy reflects Lilly's existing ambition to sell biologics through direct-to-consumer channels, similar to its LillyDirect initiative.

How does Absci plan to reduce drug development costs?

Absci's thesis is to use AI-designed drugs plus clinical trials run in China at a fraction of U.S. cost to compress the path from target to Phase 2 proof-of-concept from $150 million（約240億円） to $15–$20 million（約32億円）.